Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02498418 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 739
- Enrollment target
NCT02498418 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 739 participants.
The verdict
NCT02498418, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 739 participants
- Enrollment target
Study Summary
The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in participants with travelers' diarrhea.
Interventions
- DRUG Rifaximin
- DRUG Placebo Tablet
- DRUG Xifaxan®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 739 participants |
| Start Date | 2016-01-06 |
| Est. Completion | 2017-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02498418
The ClinicalTrials.gov registry entry for NCT02498418 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 739 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifaximin is the first listed.
NCT02498418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02498418 about?
NCT02498418 is a clinical study titled "Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea". The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in participants with travelers' diarrhea.
What is the current status of trial NCT02498418?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 739 participants. The study started on 2016-01-06. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT02498418?
The interventions under investigation include: Rifaximin (DRUG), Placebo Tablet (DRUG), Xifaxan® (DRUG).
Who is sponsoring clinical trial NCT02498418?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.